Probiotics Clostridium butyricum and Bacillus subtilis ameliorate intestinal tumorigenesis

Future Microbiology

Volumn 10, Issue 9, 2015, Pages 1433-1445

  Chen, Zhao Fei ^a   Ai, Luo Yan ^a   Wang, Ji Lin ^a   Ren, Lin Lin ^a   Yu, Ya Nan ^a   Xu, Jie ^a   Chen, Hao Yan ^a   Yu, Jun ^b   Li, Min ^a   Qin, Wen Xin ^a   Ma, Xiong ^a   Shen, Nan ^a   Chen, Ying Xuan ^a   Hong, Jie ^a   Fang, Jing Yuan ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

colorectal cancer; gut microbiota; immunity; inflammation

Indexed keywords

1,2 DIMETHYLHYDRAZINE; MESSENGER RNA; PROBIOTIC AGENT; TRANSCRIPTION FACTOR; CONDITIONED MEDIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BACILLUS SUBTILIS; CANCER INCIDENCE; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE ARREST; CELL PROLIFERATION; CLOSTRIDIUM BUTYRICUM; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNITY; INFLAMMATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VOLUME; ANIMAL; C57BL MOUSE; CELL CYCLE CHECKPOINT; CHEMICALLY INDUCED; COLORECTAL NEOPLASMS; CONDITIONED MEDIUM; DISEASE COURSE; HOMEOSTASIS; ORAL DRUG ADMINISTRATION; PHYSIOLOGY; TUMOR CELL LINE;

1,2-DIMETHYLHYDRAZINE; ADMINISTRATION, ORAL; ANIMALS; APOPTOSIS; BACILLUS SUBTILIS; CARCINOGENESIS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CLOSTRIDIUM BUTYRICUM; COLORECTAL NEOPLASMS; CULTURE MEDIA, CONDITIONED; DISEASE PROGRESSION; HOMEOSTASIS; INFLAMMATION; MALE; MICE, INBRED C57BL; PROBIOTICS;

EID: 84942809028     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.15.66     Document Type: Article

References (41)

1. Wang T, Cai G, Qiu Y et al. Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers. ISME J. 6(2), 320-329 (2012).
2. Zhang L, Cao GT, Zeng XF et al. Effects of clostridium butyricum on growth performance, immune function, and cecal microflora in broiler chickens challenged with Escherichia coli k88. Poultry Sci. 93(1), 46-53 (2014).
3. Zhang HQ, Ding TT, Zhao JS et al. Therapeutic effects of Clostridium butyricum on experimental colitis induced by oxazolone in rats. World J. Gastroenterol. 15(15), 1821-1828 (2009).
4. Kong Q, He GQ, Jia JL, Zhu QL, Ruan H. Oral administration of Clostridium butyricum for modulating gastrointestinal microflora in mice. Curr. Microbiol. 62(2), 512-517 (2011).
5. Takahashi M, Taguchi H, Yamaguchi H, Osaki T, Komatsu A, Kamiya S. The effect of probiotic treatment with Clostridium butyricum on enterohemorrhagic Escherichia coli o157: H7 infection in mice. FEMS Immunol. Med. Microbiol. 41(3), 219-226 (2004).
6. Chen HM, Yu YN, Wang JL et al. Decreased dietary fiber intake and structural alteration of gut microbiota in patients with advanced colorectal adenoma. Am. J. Clin. Nutr. 97(5), 1044-1052 (2013).
7. Volker U, Hecker M. From genomics via proteomics to cellular physiology of the Gram-positive model organism Bacillus subtilis. Cell. Microbiol. 7(8), 1077-1085 (2005).
8. Fujiya M, Musch MW, Nakagawa Y et al. The Bacillus subtilis quorum-sensing molecule CSF contributes to intestinal homeostasis via OCTN2, a host cell membrane transporter. Cell Host Microbe 1(4), 299-308 (2007).
9. Chen S, Fu Y, Liu LL et al. Live combined Bacillus subtilis and Enterococcus faecium ameliorate murine experimental colitis by immunosuppression. Int. J. Inflamm. 2014, 878054 (2014).
10. Rescigno M. Intestinal microbiota and its effects on the immune system. Cell. Microbiol. 16(7), 1004-1013 (2014).
11. Cho JH. The genetics and immunopathogenesis of inflammatory bowel disease. Nat. Rev. Immunol. 8(6), 458-466 (2008).
12. Li Y, Deuring J, Peppelenbosch MP, Kuipers EJ, De Haar C, Van Der Woude CJ. IL-6-induced DNMT1 activity mediates SOCS3 promoter hypermethylation in ulcerative colitis-related colorectal cancer. Carcinogenesis 33(10), 1889-1896 (2012).
13. Rakoff-Nahoum S, Medzhitov R. Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science 317(5834), 124-127 (2007).
14. Su LK, Kinzler KW, Vogelstein B et al. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 256(5057), 668-670 (1992).
15. Kostic AD, Chun E, Robertson L et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor immune microenvironment. Cell Host Microbe 14(2), 207-215 (2013).
16. Rosenberg DW, Giardina C, Tanaka T. Mouse models for the study of colon carcinogenesis. Carcinogenesis 30(2), 183-196 (2009).
17. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. Cancer J. Clin. 64(1), 9-29 (2014).
18. Yam C, Zhao M, Hayashi K et al. Monotherapy with a tumor-targeting mutant of S. typhimurium inhibits liver metastasis in a mouse model of pancreatic cancer. J. Surg. Res. 164(2), 248-255 (2010).
19. Hiroshima Y, Zhang Y, Murakami T et al. Efficacy of tumor-targeting Salmonella typhimurium A1-R in combination with anti-angiogenesis therapy on a pancreatic cancer patient-derived orthotopic xenograft (PDOX) and cell line mouse models. Oncotarget 5(23), 12346-12357 (2014).
20. Hiroshima Y, Zhao M, Maawy A et al. Efficacy of Salmonella typhimurium A1-R versus chemotherapy on a pancreatic cancer patient-derived orthotopic xenograft (PDOX). J. Cell. Biochem. 115(7), 1254-1261 (2014).
21. Momiyama M, Zhao M, Kimura H et al. Inhibition and eradication of human glioma with tumor-targeting Salmonella typhimurium in an orthotopic nude-mouse model. Cell Cycle 11(3), 628-632 (2012).
22. Kimura H, Zhang L, Zhao M et al. Targeted therapy of spinal cord glioma with a genetically modified Salmonella typhimurium. Cell Prolif. 43(1), 41-48 (2010).
23. Miwa S, Zhang Y, Baek KE et al. Inhibition of spontaneous and experimental lung metastasis of soft-tissue sarcoma by tumor-targeting Salmonella typhimurium A1-R. Oncotarget 5(24), 12849-12861 (2014).
24. Hayashi K, Zhao M, Yamauchi K et al. Systemic targeting of primary bone tumor and lung metastasis of high-grade osteosarcoma in nude mice with a tumorselective strain of Salmonella typhimurium. Cell Cycle 8(6), 870-875 (2009).
25. Matsumoto Y, Miwa S, Zhang Y et al. Efficacy of tumor-targeting Salmonella typhimurium A1-R on nude mouse models of metastatic and disseminated human ovarian cancer. J. Cell. Biochemi. 115(11), 1996-2003 (2014).
26. Guarner F, Malagelada JR. Gut flora in health and disease. Lancet 361(9356), 512-519 (2003).
27. Rafter J. The effects of probiotics on colon cancer development. Nutr. Res. Rev. 17(2), 277-284 (2004).
28. Uccello M, Malaguarnera G, Basile F et al. Potential role of probiotics on colorectal cancer prevention. BMC Surg. 12(Suppl. 1), S35 (2012).
29. Mohania D, Kansal VK, Kruzliak P, Kumari A. Probiotic Dahi containing Lactobacillus acidophilus and Bifidobacterium bifidum modulates the formation of aberrant crypt foci, mucin depleted foci and cell proliferation on 1, 2-dimethylhydrazine induced colorectal carcinogenesis in wistar rats. Rejuv. Res. 325-333 (2014).
30. Verma A, Shukla G. Probiotics Lactobacillus rhamnosus GG, Lactobacillus acidophilus suppresses DMH-induced procarcinogenic fecal enzymes and preneoplastic aberrant crypt foci in early colon carcinogenesis in Sprague Dawley rats. Nutr. Cancer 65(1), 84-91 (2013).
31. Arimochi H, Kinouchi T, Kataoka K, Kuwahara T, Ohnishi Y. Effect of intestinal bacteria on formation of azoxymethaneinduced aberrant crypt foci in the rat colon. Biochem. Biophys. Res. Commun. 238(3), 753-757 (1997).
32. Ohkawara S, Furuya H, Nagashima K, Asanuma N, Hino T. Oral administration of Butyrivibrio fibrisolvens, a butyrate-producing bacterium, decreases the formation of aberrant crypt foci in the colon and rectum of mice. J. Nutr. 135(12), 2878-2883 (2005).
33. Chen HM, Lin YW, Wang JL, Kong X, Hong J, Fang JY. Identification of potential target genes of butyrate in dimethylhydrazineinduced colorectal cancer in mice. Nutr. Cancer 65(8), 1171-1183 (2013).
34. Isono A, Katsuno T, Sato T et al. Clostridium butyricum TO-A culture supernatant downregulates TLR4 in human colonic epithelial cells. Dig. Dis. Sci. 52(11), 2963-2971 (2007).
35. Ohnmacht C, Marques R, Presley L, Sawa S, Lochner M, Eberl G. Intestinal microbiota, evolution of the immune system and the bad reputation of pro-inflammatory immunity. Cell. Microbiol. 13(5), 653-659 (2011).
36. He D, Li H, Yusuf N et al. IL-17 mediated inflammation promotes tumor growth and progression in the skin. PLoS ONE 7(2), e32126 (2012).
37. Wang L, Yi T, Zhang W, Pardoll DM, Yu H. IL-17 enhances tumor development in carcinogen-induced skin cancer. Cancer Res. 70(24), 10112-10120 (2010).
38. Wu SG, Rhee KJ, Albesiano E et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type
39. T cell responses. Nat. Med. 15(9), 1016-1022 (2009).
40. Gartel AL, Radhakrishnan SK. Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res. 65(10), 3980-3985 (2005).
41. Xiong H, Zhang ZG, Tian XQ et al. Inhibition of JAK1, 2/STAT3 signaling induces apoptosis, cell cycle arrest, and reduces tumor cell invasion in colorectal cancer cells. Neoplasia 10(3), 287-297 (2008).